Condition: Gastrointestinal Neoplasms · Sponsor: GlaxoSmithKline
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Los Alamitos, California, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | Santa Monica, California, United States | Recruiting |
| GSK Investigational Site | Whittier, California, United States | Recruiting |
| GSK Investigational Site | Aurora, Colorado, United States | Recruiting |
| GSK Investigational Site | New York, New York, United States | Recruiting |
| GSK Investigational Site | New York, New York, United States | Recruiting |
| GSK Investigational Site | Durham, North Carolina, United States | Recruiting |
| GSK Investigational Site | Houston, Texas, United States | Recruiting |
| GSK Investigational Site | San Antonio, Texas, United States | Recruiting |
| GSK Investigational Site | Wenatchee, Washington, United States | Recruiting |
| GSK Investigational Site | Madison, Wisconsin, United States | Recruiting |
+ 73 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06885034